# A point prevalence survey and monitoring indicator research on the second batch of national key monitoring and rational use drugs

**Authors:** Li Tang, Hongmei Liu, Shasha Wu, Jing Liu, Xiaoyu Jiang, Yuanyuan Fu, Na Tao, Yong He

PMC · DOI: 10.3389/fphar.2024.1416010 · 2024-07-05

## TL;DR

This study examines the usage of a new set of monitored drugs in China and finds that a specific metric better reflects their actual use.

## Contribution

The study introduces a more accurate monitoring indicator (DOT) for the second batch of national key monitored drugs compared to traditional metrics.

## Key findings

- 29.20% of patients received at least one of the second NKMRUDs.
- DOT was found to be more accurate than DDD in reflecting drug consumption.

## Abstract

With the remarkable effect of controlling the increase in drug costs by the first batch of National Key Monitoring and Rational Use Drugs (first NKMRUDs), the National Health Commission of the People’s Republic of China releases the second NKMRUDs to further strengthen the reasonable use of drugs. Unfortunately, the second NKMRUDs include some drugs of National Volume-based Procurement and National Essential Medicines, which challenges the management of pharmaceutical affairs on the three kinds of drugs.

The main objective of this study was to investigate the prevalence of the second NKMRUDs and explore their monitoring indicators.

An adapted WHO methodology for point prevalence surveys was conducted for the second NKMRUDs. For the monitoring indicators, we sought to explore whether the defined daily dose (DDD) and days of therapy (DOT) can be suitable for the second NKMRUDs through comparing differences between DDD and DOT with the prescribed daily dose (PDD).

Among the 935 included patients, 29.20% of the patients received at least one of the second NKMRUDs. A total of 273 patients were administered with 487 times of the second NKMRUDs. Among them, 162 , 62 , and 49 patients were receiving one, two, and three or more agents, respectively. The most commonly prescribed second NKMRUDs were compound amino acids, budesonide, and ceftazidime. The total DDDs and DOTs of the second NKMRUDs were 3360.68 and 1819.80, respectively, with the PDDs of 1865.26. The deviations (80.17%) of DDDs from PDDs were significantly greater than those (−2.44%) of DOTs.

The prevalence of the second NKMRUDs was obtained by using the adapted PPS methodology at a tertiary university hospital. The DOT indicator is found to more accurately reflect actual consumption than the DDD indicator for second NKMRUDs. It is recommended to use the DOT indicator to monitor second NKMRUDs.

## Full-text entities

- **Species:** Homo sapiens (human, species) [taxon 9606]

---
Source: https://tomesphere.com/paper/PMC11257963